Resmed (RSMDF) EPS (Basic) (2009 - 2026)

Resmed has reported EPS (Basic) for 18 years, with the latest figure at $2.74 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Basic) rose 10.04% year-over-year to $2.74; the trailing twelve-month figure through Mar 2026 stood at $10.4 (up 16.33% YoY), and the FY2025 full-year result was $9.55, up 37.61% from the prior year.
• EPS (Basic) for Q1 2026 stood at $2.74, up from $2.69 in the prior quarter.
• The five-year high for EPS (Basic) was $2.74 in Q1 2026, with the low at $1.22 in Q1 2022.
• Historically, EPS (Basic) has averaged $1.94 across 5 years, with a median of $1.98 in 2024.
• Annual changes were most pronounced in 2022 — EPS (Basic) soared 325.93% — and 2023, when it dropped 7.19%.
• Resmed's EPS (Basic) stood at $1.53 in 2022, then dropped by 7.19% to $1.42 in 2023, then surged by 65.49% to $2.35 in 2024, then climbed by 14.47% to $2.69 in 2025, then grew by 1.86% to $2.74 in 2026.
• The last three EPS (Basic) figures came in at $2.74 (Q1 2026), $2.69 (Q4 2025), and $2.38 (Q3 2025), per Business Quant data.